Latest news
Darlifarnib Plus Cabozantinib Shows Durable Activity in Advanced RCC - Targeted OncologyTargeted Oncology · Mon, 27 Jul 2026 15:10:16 GMTKura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026 - Yahoo FinanceYahoo Finance · Mon, 27 Jul 2026 07:00:00 GMTKura's Drug Combo Shows 13-Month Median Without Progression - Stock TitanStock Titan · Mon, 27 Jul 2026 07:00:00 GMT